1332 — Touyun Biotech Balance Sheet
0.000.00%
- HK$799.59m
- HK$1.25bn
- HK$159.97m
Annual balance sheet for Touyun Biotech, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 254 | 94 | 144 | 36 | 69.6 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 171 | 132 | 132 | 97 | 64.8 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 469 | 268 | 322 | 162 | 174 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 172 | 436 | 381 | 311 | 280 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Total Assets | 972 | 1,025 | 888 | 607 | 550 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 407 | 530 | 410 | 381 | 558 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Liabilities | 484 | 555 | 624 | 608 | 634 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 488 | 470 | 264 | -0.848 | -83.2 |
| Total Liabilities & Shareholders' Equity | 972 | 1,025 | 888 | 607 | 550 |
| Total Common Shares Outstanding |